Your SlideShare is downloading. ×
Valerio Carelli, Convegno Mitocon 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Valerio Carelli, Convegno Mitocon 2013

790
views

Published on

Risultati sull'uso dell'EPI-743 in diverse sindromi in pazienti adulti …

Risultati sull'uso dell'EPI-743 in diverse sindromi in pazienti adulti
Valerio Carelli, Università di Bologna

Published in: Health & Medicine, Education

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
790
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Terapia con EPI-743 inpazientiadulti (LHON e NARP)Valerio Carelli, MD, PhDLaboratorio di Neurogenetica, Dipartimento diScienzeBiomedicheeNeuroMotorie (DIBINEM),Universita’ di BolognaIRCCS Istituto di ScienzeNeurologiche di Bologna,OspedaleBellaria, Bologna
  • 2. LHONND1 (3460)ND4 (11778) ND6 (14484)Difetto del Complesso I
  • 3. STORIA NATURALE DELLA LHONBarboni et al., Ophthalmology 2010
  • 4. Pattern specifico di neurodegenerazione
  • 5. Questo pattern e’caratterizzatodallavulnerabilita’dellefibrenervose a calibrominore
  • 6. 63
  • 7. CONTROLLO LHON/3460
  • 8. • Females may be partially protected from LHONby estrogens,which activate mitochondrialbiogenesis• Increased mitochondrial biogenesis is asuccessful compensatory strategy thatinfluences penetrance (now we are hunting thenuclear modifying genes relevant to thismechanism)• Estrogen-like drugs and strategies to increasemitochondrial biogenesis may be relevant fortherapy
  • 9. RECUPERO DI FUNZIONEVISIVA
  • 10. TERAPIA PER LA LHON• Idebenone and EPI-743• Anti-apoptotic drugs for acute phase• Activation of mitochondrial biogenesis forcarriers• Gene therapy: allotopic expression• Gene therapy: xenotopic expression ofalternative oxidase (S. Cervisiae singlesubunit NADH oxidase Ndi1)
  • 11. Idebenone
  • 12. CONCLUSIONSIdebenone treated patients with the 11778/ND4mutation had significantly increased rate ofvisual recovery compared to untreatedThe duration of therapy was longer for patientsrecovering vision and earlier start of therapycorrelated with earlier onset of visual recovery “in-between eyes” idebenone treatment did notspare the second eye
  • 13. EPI-743
  • 14. Complete reversion Partial recovery ProgressionLHON patients treated with EPI-743 at Doheny Eye Institute(courtesy Prof. Alfredo A. Sadun)
  • 15. Trepazientiitalianitrattati con EPI-743• 300 mg x 3/die• Stadioprecoce di malattia, con coinvolgimentosolo monolaterale• Due con mutazione 11778/ND4 euno con3460/ND1
  • 16. PATIENT 1 – LHON/3460
  • 17. PATIENT 2 – LHON/11778
  • 18. Patient 3 – LHON/11778
  • 19. Perinatal hypoxia:hemianopsia at visual field
  • 20. Lactic acid after standardizedeffort is ameliorated byEPI-743
  • 21. Conclusioni• 1 paziente con recuperoparziale• 1 pazientesenzarispostaterapeutica• 1 paziente con recuperoerisparmio delsecondoocchio• Neipazienti USA (n=12) stessapercentuale disuccessoterapeutico (2 casi concompletaregressionedellamalattiaeassenza diperdita di fibre=malattiaabortita)• NeipazientiBrasiliani (n=6), tutti conmalattiacronica, 2 hannobeneficiato di unrecupero di funzionevisiva
  • 22. Unafamiglia NARP (3 pazienti) trattatacon EPI-743 da circa 8 mesi
  • 23. Ax 3D FSPGR T1 Ax FLAIR T2 Cor FSE T2PRE- EPI 743POST- EPI 743(3 mesi)
  • 24. Ax T2FSE Ax T2 FLAIR Cor FSE T2POST-EPI 743( 7 mesi)
  • 25. Lab of Neurogenetics:-Valerio Carelli, MD, PhD-Maria Lucia Valentino, MD-Chiara La Morgia, MD, PhD-Sabrina Farne, lab technician’-Luisa Iommarini, BiotechSc-Leonardo Caporali, BiotechSc-Alessandra Maresca, BiotechSc

×